# Gunnar B. Kristensen

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/gunnar-b-kristensen/

## Facts

| Field | Value |
| --- | --- |
| Citations | 25,253 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 71 |
| i10-index | 225 |
| Last Known Institution | Oslo University Hospital |
| OpenAlex ID | https://openalex.org/A5018546041 |
| ORCID iD | https://orcid.org/0000-0001-6231-7247 |
| Works | 429 |

## Researcher papers

- [Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer](https://scholariq.org/papers/neoadjuvant-chemotherapy-or-primary-surgery-in-stage-iiic-or-iv-ovarian-cancer/)
- [A Phase 3 Trial of Bevacizumab in Ovarian Cancer](https://scholariq.org/papers/a-phase-3-trial-of-bevacizumab-in-ovarian-cancer/)
- [Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial](https://scholariq.org/papers/bevacizumab-combined-with-chemotherapy-for-platinum-resistant-recurrent-ovarian/)
- [Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial](https://scholariq.org/papers/paclitaxel-plus-platinum-based-chemotherapy-versus-conventional-platinum-based/)
- [Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial](https://scholariq.org/papers/standard-chemotherapy-with-or-without-bevacizumab-for-women-with-newly-diagnosed/)
- [Gene Expression Patterns in Ovarian Carcinomas](https://scholariq.org/papers/gene-expression-patterns-in-ovarian-carcinomas/)
- [Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials](https://scholariq.org/papers/neoadjuvant-chemotherapy-versus-debulking-surgery-in-advanced-tubo-ovarian/)
- [Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase](https://scholariq.org/papers/operability-and-chemotherapy-responsiveness-in-advanced-low-grade-serous-ovarian/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [Radiomics and Machine Learning in Medical Imaging](https://scholariq.org/topics/radiomics-and-machine-learning-in-medical-imaging/)
- [Cancer, Hypoxia, and Metabolism](https://scholariq.org/topics/cancer-hypoxia-and-metabolism/)
- [Cervical Cancer and HPV Research](https://scholariq.org/topics/cervical-cancer-and-hpv-research/)

## Researcher university

- [Oslo University Hospital](https://scholariq.org/institutions/oslo-university-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.